RBX 2660

Drug Profile

RBX 2660

Alternative Names: Fecal Microbiota for Transplantation (FMT) product - Rebiotix; Microbiota restoration therapy - Rebiotix; Microbiota suspension - Rebiotix; RBX-2660

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Rebiotix
  • Class Antibacterials; Antidiarrhoeals; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Clostridium infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Clostridium infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Clostridium infections
  • Phase 0 Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 26 Oct 2016 Adverse events and efficacy data from the phase II PUNCHCD2 trial in Clostridium infections presented at the IDWeek 2016
  • 17 Oct 2016 Rebiotix completes the phase IIb PUNCH CD 2 trial for Clostridium infections (Recurrent) in USA and Canada
  • 17 Oct 2016 Rebiotix plans a phase III trial in Clostridium infections (Recurrent)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top